23434-96-0

Usage

Uses

Used in Scientific Research:
Methyl 4-chloro-3-phenylalaninate is used as a research compound for [application reason], such as studying its chemical properties, potential interactions with biological systems, or its role in various biochemical processes. Its structure and modifications may provide insights into the understanding of amino acid derivatives and their potential applications in the field of chemistry and biology.
Used in Pharmaceutical Development:
Methyl 4-chloro-3-phenylalaninate is used as a potential pharmaceutical compound for [application reason], such as exploring its therapeutic potential in the treatment of diseases or disorders. The presence of the 'methyl' and '4-chloro' groups may confer new properties or activities that could be beneficial in drug design and development.
Used in Chemical Synthesis:
Methyl 4-chloro-3-phenylalaninate is used as a synthetic intermediate for [application reason], such as in the preparation of more complex molecules or in the synthesis of other chemical compounds. Its unique structure may serve as a building block or a key component in the creation of novel substances with specific properties or functions.
Used in Material Science:
Methyl 4-chloro-3-phenylalaninate is used as a component in the development of new materials for [application reason], such as in the creation of advanced polymers, coatings, or other materials with unique properties. The incorporation of methyl 4-chloro-3-phenylalaninate into material formulations may lead to the discovery of new applications and uses in various industries.

InChI:InChI=1/C10H12ClNO2/c1-14-10(13)9(12)6-7-2-4-8(11)5-3-7/h2-5,9H,6,12H2,1H3

Upstream product

• 1332883-27-8 (E)-methyl 3-(4-chlorophenyl)-2-(hydroxyimino)propanoate 
• 673-41-6 p-chlorobenzenediazonium tetrafluoroborate 
• 67-56-1 methanol 
• 7424-00-2 DL-Phe(4Cl) 
• 131469-67-5 methyl 2-[1-hydroxy-1-(4-chlorophenyl)methyl]acrylate 
• 104-88-1 4-chlorobenzaldehyde 
• 131469-72-2 methyl 3-acetoxy-3-(4-chlorophenyl)-2-methylenepropanoate 
• 53101-00-1 methyl 3-(4-chlorophenyl)-2-oxopropanoate 

Downstream Products

• 182492-19-9 2-(N-tert-butyloxycarbonyl-N-methyl)-amino-3-(4-chlorophenyl)-propionaldehyde 
• 182492-20-2 N-tert-butyloxycarbonyl-N-methyl-4-chlorophenylalanine methyl ester 
• 605680-66-8 methyl 2-diazo-3(4-chlorophenyl)propanoate 
• 605680-75-9 ethyl 3-(4-chlorophenyl)-2-pyrrolidin-N-yl-propanoate 
• 859995-83-8 4-chloro-N-nicotinoyl-DL-phenylalanin-amide 
• 123795-34-6 2-tert-butoxycarbonylamino-3-(4-chloro-phenyl)-propionic acid methyl ester 

Relevant academic research and scientific papers

Identification of inhibitors of UDP-galactopyranose mutaseviacombinatorialin situscreening

Anin situscreening assay for UDP-galactopyranose mutase (UGM, an essential enzyme ofM. tuberculosiscell wall biosynthesis) has been developed to discover novel UGM inhibitors. The approach is based on the amide-forming reaction of an amino acid core with various cinnamic acids, followed by a direct fluorescence polarization assay to identify the best UGM binders without isolation and purification of the screened ligands. This assay allows us to perform one-pot high-throughput synthesis and screening of enzyme inhibitors in a 384-well plate format. UGM ligands were successfully identified by this technology and their inhibition levels were established from pure synthetic compoundsin vitroand in a whole cell antibacterial assay. This study provides a blueprint for designing enamide structures as new UGM inhibitors and anti-mycobacterial agents.

HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.

A versatile approach to noncoded β-hydroxy-α-amino esters and α-amino acids/esters from morita-baylis-hillman adducts

A simple and straightforward approach to the diastereoselective synthesis of noncoded β-hydroxy-α-amino esters from Morita-Baylis-Hillman (MBH) adducts is described. The strategy is based on a one-pot sequence involving an oxidative cleavage of the double bond of silylated Morita-Baylis-Hillman adducts, followed by the reaction with hydroxylamine hydrochloride/pyridine to form oximes. The stereoselective reduction of the oximes with the mixture MoCl5·nH2O/NaBH3CN led to the corresponding anti-β-hydroxy-α-amino esters in four steps in good overall yield and with diastereoselectivity higher than 95%. A slight modification of the synthetic approach has allowed for the racemic synthesis of a set of noncoded α-amino esters/acids and DOPA

Fixation and recycling of nitrogen monoxide through carbonitrosation reactions

The removal of nitrogen monoxide from gas streams through complexation to iron(ii) ions in aqueous dimethylsulfoxide can be combined with a new variant of the Meerwein arylation, which incorporates the previously complexed NO into organic compounds to give oximes as final products. The first step of this two-step process has been evaluated regarding the effectiveness of the NO absorption and the sensitivity of the aqueous iron(ii)-DMSO solution towards oxygen from air, in both cases in comparison with the known BioDeNOx process. The subsequent Meerwein arylation, which was designed with the intention to make use of nitrogen monoxide as the simplest nitrogen-centered radical scavenger, is shown to tolerate an exceptionally broad spectrum of substituents on the aromatic core of the diazonium salts including electron-donating as well as electron-withdrawing substituents. Under simple conditions the resulting oximes can be converted to racemic amino acid esters. This journal is the Partner Organisations 2014.